scholarly journals FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
P. Hillmen ◽  
J. C. Byrd ◽  
P. Ghia ◽  
A. P. Kater ◽  
A. Chanan‐Khan ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
First Results ◽  
Previously Treated

CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

2021 ◽  
Vol 21 ◽  
pp. S318
Author(s):  
John C. Byrd ◽  
Peter Hillmen ◽  
Paolo Ghia ◽  
Arnon P. Kater ◽  
Asher Chanan-Khan ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
First Results ◽  
Previously Treated

scholarly journals Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

2017 ◽  
Vol 7 (2) ◽  
pp. e524-e524 ◽  
Author(s):  
M Montillo ◽  
S O'Brien ◽  
A Tedeschi ◽  
J C Byrd ◽  
C Dearden ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Previously Treated ◽  
Autoimmune Cytopenias

Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia

2003 ◽  
Vol 21 (7) ◽  
pp. 1278-1284 ◽  
Author(s):  
Mark A. Weiss ◽  
Peter G. Maslak ◽  
Joseph G. Jurcic ◽  
David A. Scheinberg ◽  
Timothy B. Aliff ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Response Rate ◽  
Median Number ◽  
Lymphocytic Leukemia ◽  
Severe Nausea ◽  
Treatment Regimens ◽  
Purine Analogs ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Grade 3

Purpose: Purine analogs and alkylators are important agents in the treatment of chronic lymphocytic leukemia (CLL). Previously, combinations of fludarabine and chlorambucil were abandoned because of increased toxicity from overlapping myelosuppression and immunosuppression. Of the purine analogs active in CLL, pentostatin may be least myelosuppressive. We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs. Patients and Methods: We studied 23 patients with previously treated CLL. All patients received pentostatin 4 mg/m2. Seventeen patients received cyclophosphamide 600 mg/m2, and six patients received cyclophosphamide 900 mg/m2. Both drugs were administered on day 1 of each cycle, and cycles were repeated every 3 weeks for six treatments. Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were administered prophylactically. The median number of prior treatment regimens was three (range, one to five) with 13 patients (57%) refractory to prior fludarabine therapy. Results: The cyclophosphamide 900 mg/m2 dose level was associated with moderate to severe nausea, and we chose cyclophosphamide 600 mg/m2 as the dose for further study. There were 17 responses (74%; 95% confidence interval, 63% to 85%), including four complete responses. The response rate was 77% in fludarabine-refractory patients. Myelosuppression was acceptable with grade 3/4 neutropenia and thrombocytopenia, seen in 35% and 30% of patients, respectively. The relative sparing of thrombopoiesis can be seen in that only one patient (5%) with an initial platelet count of more than 20,000 required platelet transfusions while receiving therapy. Conclusion: Pentostatin 4 mg/m2 with cyclophosphamide 600 mg/m2 is safe and effective in previously treated patients with CLL. On the basis of these results, we are currently studying pentostatin, cyclophosphamide, and rituximab (PCR) therapy in patients with CLL.

A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients

2010 ◽  
Vol 68 (3) ◽  
pp. 643-651 ◽  
Author(s):  
Jonathan Hebb ◽  
Sarit Assouline ◽  
Caroline Rousseau ◽  
Pierre DesJardins ◽  
Stephen Caplan ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Phase I ◽  
Imatinib Mesylate ◽  
Phase I Study ◽  
Lymphocytic Leukemia ◽  
Previously Treated

scholarly journals Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

2011 ◽  
Vol 53 (2) ◽  
pp. 211-217 ◽  
Author(s):  
Clive S. Zent ◽  
Brian J. Smith ◽  
Zuhair K. Ballas ◽  
James E. Wooldridge ◽  
Brian K. Link ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chronic Lymphocytic Leukemia ◽  
Phase I ◽  
Lymphocytic Leukemia ◽  
Phase I Clinical Trial ◽  
Cpg Oligonucleotide ◽  
Previously Treated

The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4819-4819
Author(s):  
Tadeusz Robak ◽  
Jerzy Z. Blonski ◽  
Marek Kasznicki ◽  
Joanna Gora-Tybor ◽  
Anna Dmoszynska ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Median Survival ◽  
Lymphocytic Leukemia ◽  
Late Relapse ◽  
Line Treatment ◽  
Second Line ◽  
Previous Response ◽  
Secondary Neoplasms ◽  
Significant Difference ◽  
Previously Treated

Abstract Previously, we reported a study on efficacy and toxicity of cladribine (2-CdA) + prednisone (P) compared with chlorambucil (Chl) + P in previously untreated patients with progressive or symptomatic chronic lymphocytic leukemia (CLL) in a randomized multicenter trial (Blood2000, 96, 2723). Of 229 patients enrolled, 126 received 2-CdA+P and 103 received Chl+P. Here, we present the long-term follow-up and the results of subsequent treatment in refractory or relapsed patients. Patients with non responsive (NR) disease or with progression after 3 courses of 2-CdA + P or Chl+P or who relapsed earlier then 12 months after completing the treatment were switched to an alternative arm. Patients who relapsed later than 12 months from first remission (late relapse) were retreated with the same schedule that induced previous response. In 50 patients, non-responsive or with early relapse, treated originally with Chl+P who received 2-CdA+P as second line, complete response (CR) was achieved in 12 (24%) and overall response (OR) in 32 (64%). Twenty eight patients originally treated with 2-CdA+P received Chl+P and CR and OR was obtained in 1 (3,6%) and in 6 (21.4%), respectively (p=0.002 for both arms). Thirty three patients with late relapse were retreated with 2-CdA+P and 19 patients were retreated with Chl+P. OR (CR) was 54.6% (6.1%) and 47.4% (15.8%), respectively (p=0.34). The third line treatment was CHOP in both arms. Twenty seven patients from 2-CdA+P group and 37 patients from Chl+P group were treated with CHOP and only one patient responded. Median survival was 3.3 and 3.75 years, respectively (p=0.63). Secondary neoplasms were observed in 8 (6.4%) patients treated with 2-CdA+P and in 4 (3.9%) treated with Chl+P as first line treatment (p=0.6). Death rates have been similar in patients treated originally with 2-CdA+P 82 (64.6%) and Chl+P 69 (66.4%) (p=0.8). In conclusion, cladribine is significantly more effective as a second line treatment than chlorambucil. Both agents are similarly effective in retreatment of late relapsed patients. CHOP is of no value in patients previously treated with 2-CdA + P and with Chl + P. There is no significant difference in median survival of patients treated initially with Chl + P and 2-CdA + P.

Sign in / Sign up

Export Citation Format

Share Document